$AKTS

$15.73 +$0.00 (0.0%) Close

$AKTS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 55.3M shares outstanding

Who owns AKTS?

By type of holder

Institutions 61.8% Insiders 15.2% Everyone else 23.0%

Concentration Top 10 holders own 105.5%

Ansbert Gadicke 18.6% · Eli Lilly and Company 11.5%

Institutional ownership

61.8%

-1.8 pts vs last qtr

Institutional holders

113

+44 vs last qtr

Net shares bought

−1.0M

by institutions in Q2 2026

New / sold out

52 / 8

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Jupiter Topco LLC NEW +1.3M
TCG Crossover Management, LLC NEW +696.6K

Biggest sellers in Q2 2026

Janus Henderson Group PLC SOLD OUT −1.5M
Price T Rowe Associates Inc /MD/ −800.7K

Who is planning to sell?

Notices of proposed sale, last 12 months

$3.53M

5 notices from 4 people

Shares covered

132.9K

0.24% of the company

Arranged in advance

16%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Akos Czibere Officer $1.39M
Shulamit Ron-Bigger Officer $1.39M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

There are not yet two fiscal years of reported share counts for Aktis Oncology Inc.

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years0% Under 1 year100%

Quarterly turnover

10.8%

of institutional shares changed hands

Top 10 managers, median time held

1 quarter

Super Investors

Investment managers reporting AKTS on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
MB MPM Bioimpact LLC	4.8M	8.74%	Unchanged	Q1 '26	9.5%
Shares held by quarter Peak holding4.8M (Q1'26) Change over 8 quarters+4.8M Share of the company8.740% MPM Bioimpact LLC's full portfolio →
EC EcoR1 Capital, LLC 13D · 9.1%	4.8M	8.72%	Unchanged	Q1 '26	7.6%
Shares held by quarter Peak holding4.8M (Q1'26) Change over 8 quarters+4.8M Share of the company8.720% Disclosed stake13D · 9.1% EcoR1 Capital, LLC's full portfolio →

MPM Bioimpact LLC

4.8M

% of company

8.74%

Change vs last qtr

Unchanged

Held since

Q1 '26

EcoR1 Capital, LLC

13D · 9.1%

4.8M

% of company

8.72%

Change vs last qtr

Unchanged

Held since

Q1 '26

28 more super investors behind a free account

See every manager holding Aktis Oncology Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting AKTS on Form N-PORT; together they hold 12.9% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VH Vanguard Health Care Fund Vanguard Specialized Funds	$32.3M	1.5M	2.64%	0.08%	July 31, 2026
TR T. Rowe Price Small-Cap Stock Fund, Inc. T. Rowe Price Small-Cap Stock Fund, Inc.	$21.8M	676.6K	1.22%	0.23%	June 30, 2026

Vanguard Health Care Fund

Vanguard Specialized Funds

Position value

$32.3M

% of company

2.64%

% of the fund

0.08%

As of

July 31, 2026

T. Rowe Price Small-Cap Stock Fund, Inc.

Position value

$21.8M

% of company

1.22%

% of the fund

0.23%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Aktis Oncology Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
AG Ansbert Gadicke 5%+ holder 13D · 19.3%	10.3M	18.55%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company18.550% Disclosed stake13D · 19.3% View the 13D/G filing →
EL Eli Lilly and Company 5%+ holder 13D · 11.9%	6.3M	11.47%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company11.470% Disclosed stake13D · 11.9% View the 13D/G filing →

Ansbert Gadicke

5%+ holder13D · 19.3%

10.3M

% of company

18.55%

Change vs last qtr

—

Held since

—

Eli Lilly and Company

5%+ holder13D · 11.9%

6.3M

% of company

11.47%

Change vs last qtr

—

Held since

—

20 more holders behind a free account

See every insider and 5%+ holder of Aktis Oncology Inc.

Comments